These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34275042)

  • 21. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer.
    Bilimoria KY; Bentrem DJ; Hansen NM; Bethke KP; Rademaker AW; Ko CY; Winchester DP; Winchester DJ
    J Clin Oncol; 2009 Jun; 27(18):2946-53. PubMed ID: 19364968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Axillary Dissection
    Arisio R; Borella F; Porpiglia M; Durando A; Bellino R; Bau MG; DE Sanctis C; Danese S; Benedetto C; Katsaros D
    In Vivo; 2019; 33(6):1941-1947. PubMed ID: 31662523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sentinel Lymph Node Biopsy Versus Axillary Dissection in Node-Negative Early-Stage Breast Cancer: 15-Year Follow-Up Update of a Randomized Clinical Trial.
    Canavese G; Bruzzi P; Catturich A; Tomei D; Carli F; Garrone E; Spinaci S; Lacopo F; Tinterri C; Dozin B
    Ann Surg Oncol; 2016 Aug; 23(8):2494-500. PubMed ID: 26975739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrence after sentinel lymph node biopsy with or without axillary lymph node dissection in patients with breast cancer.
    Takei H; Suemasu K; Kurosumi M; Horii Y; Yoshida T; Ninomiya J; Yoshida M; Hagiwara Y; Kamimura M; Hayashi Y; Inoue K; Tabei T
    Breast Cancer; 2007; 14(1):16-24. PubMed ID: 17244989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are the ACOSOG Z0011 Trial Findings Being Applied to Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy?
    Kantor O; Pesce C; Liederbach E; Wang CH; Winchester DJ; Yao K
    Breast J; 2017 Sep; 23(5):554-562. PubMed ID: 28295828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients.
    Schipper RJ; de Bruijn A; Voogd AC; Bloemen JG; Van Riet YE; Vriens BEP; Smidt ML; Siesling S; van der Sangen MJC; Nieuwenhuijzen GAP
    Eur J Surg Oncol; 2021 Aug; 47(8):1928-1933. PubMed ID: 34030918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of sentinel node re-mapping in patients who have second or recurrent breast cancer and had previous axillary procedures.
    Tokmak H; Kaban K; Muslumanoglu M; Demirel M; Aktan S
    World J Surg Oncol; 2014 Jul; 12():205. PubMed ID: 25016393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast cancer hormone receptor negativity, triple-negative type, mastectomy and not receiving adjuvant radiotherapy were associated with axillary recurrence after sentinel lymph node biopsy.
    Sekine C; Nakano S; Mibu A; Otsuka M; Oinuma T; Takeyama H
    Asian J Surg; 2020 Jan; 43(1):148-153. PubMed ID: 31153730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of axillary lymph node dissection after sentinel lymph node biopsy on overall survival in patients with T1 or T2 node-positive breast cancer: report from the Korean Breast Cancer Society.
    Park HS; Chae BJ; Song BJ; Jung SS; Han W; Nam SJ; Youn HJ; Ko BK; Kim DW;
    Ann Surg Oncol; 2014 Apr; 21(4):1231-6. PubMed ID: 24318094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgical Management of the Axilla in Patients with Occult Breast Cancer (cT0 N+) After Neoadjuvant Chemotherapy.
    Cohen BL; Collier AL; Kelly KN; Goel N; Kesmodel SB; Yakoub D; Moller M; Avisar E; Franceschi D; Macedo FI
    Ann Surg Oncol; 2020 Jun; 27(6):1830-1841. PubMed ID: 31989360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society.
    Imoto S; Yamauchi C; Komoike Y; Tsugawa K; Yotsumoto D; Wada N; Ueno T; Oba MS; Shien T; Sugae S; Tsuda H; Yoneyama K
    Breast Cancer; 2017 May; 24(3):427-432. PubMed ID: 27553957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
    Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ.
    Coromilas EJ; Wright JD; Huang Y; Feldman S; Neugut AI; Chen L; Hershman DL
    JAMA Oncol; 2015 Jun; 1(3):323-32. PubMed ID: 26181180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraoperative Ultrasound-Guided Excision of Axillary Clip in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Therapy (ILINA Trial) : A New Tool to Guide the Excision of the Clipped Node After Neoadjuvant Treatment.
    Siso C; de Torres J; Esgueva-Colmenarejo A; Espinosa-Bravo M; Rus N; Cordoba O; Rodriguez R; Peg V; Rubio IT
    Ann Surg Oncol; 2018 Mar; 25(3):784-791. PubMed ID: 29197044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer.
    Mariscal Martínez A; Vives Roselló I; Salazar Gómez A; Catanese A; Pérez Molina M; Solà Suarez M; Pascual Miguel I; Blay Aulina L; Ríos Gozálvez C; Julián Ibáñez JF; Rodríguez Martínez P; Martínez Román S; Margelí Vila M; Luna Tomás MA
    Surg Oncol; 2021 Mar; 36():28-33. PubMed ID: 33285433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
    Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of clinically node-negative breast cancer without axillary dissection: can preserved axilla be safely treated with radiation after a positive sentinel node biopsy?
    Sanuki N; Takeda A; Amemiya A; Ofuchi T; Ono M; Ogata H; Yamagami R; Hatayama J; Eriguchi T; Kunieda E
    Clin Breast Cancer; 2013 Feb; 13(1):69-76. PubMed ID: 23062706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
    Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
    JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis.
    Wong SM; Weiss A; Mittendorf EA; King TA; Golshan M
    Ann Surg Oncol; 2019 Oct; 26(11):3517-3525. PubMed ID: 31342389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer.
    Park S; Lee JE; Paik HJ; Ryu JM; Bae SY; Lee SK; Kim SW; Nam SJ
    Clin Breast Cancer; 2017 Feb; 17(1):e19-e29. PubMed ID: 27495997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.